The CDCO Platform is a member of a National Research Infrastructure for Australia integrated capability network that supports Small Molecule Drug Discovery. Delivered by Therapeutic Innovation Australia, these connected facilities provide expertise and infrastructure to support cutting-edge drug discovery research and boost innovation across Australia. Click on the link below for more information about the TIA voucher scheme.
MedChem Australia's purpose is to work with the Australian biomedical research and biotech community to develop new medicines through creativity and collaboration. MedChem Australia provides expert medicinal chemistry & DMPK capability to enhance and accelerate the development of new small molecule therapeutics. Three of the nation’s top medicinal chemistry groups from Monash University, WEHI and the University of Sydney, along with the Centre for Drug Candidate Optimisation make up MedChem Australia. To find out more, visit the MedChem Australia website.
We are committed to providing excellence and quality through all stages of research, industry engagement and collaboration. Quality of thinking, study design and execution are hallmarks of the CDCO Platform. This principle underpins our approach and involvement in all collaborator programs to support research excellence. We are a member of the Monash Research Platform network and are ISO 90001:2015 Quality Management certified by BSI under certificate number FS 729759.
Our lab has been certified by My Green Lab as achieving platinum status. This accreditation recognises our commitment to improving our sustainability practices and culture. We use evidence-based methods to reduce the impact of our laboratories without disrupting critical work.
